Ogbeivor Collins, Bandaru Suresh, Milton Carl
Rehabilitation Department, John Hopkins Healthcare Aramco, Dhahran, Kingdom of Saudi Arabia.
Department of Physiotherapy, East Sussex Hospital Trust, Hastings, UK.
Musculoskeletal Care. 2019 Sep;17(3):257-268. doi: 10.1002/msc.1416. Epub 2019 Aug 2.
The aim of the study was to determine the effectiveness of the lateral approach to subacromial injection, compared with the posterior approach, for the treatment of subacromial impingement syndrome.
A pragmatic randomized controlled trial was carried out in an outpatient community musculoskeletal service. The sample comprised 80 adults, aged 18 years or over, with subacromial impingement syndrome. The intervention group received a single subacromial injection, using a 21-gauge green needle, of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine using a lateral approach. The control group received identical treatment, with the exception that the injection was given using a posterior approach. The outcome measures were pain measured using 0-10 numerical pain scale and shoulder pain and disability index (SPADI) scores at 8 and 12 weeks' follow-up.
A moderate but statistically and clinically significant difference in improvement in daytime pain (mean change in score) occurred in favour of the lateral group (mean = 4.0) compared with the posterior group (mean = 2.0) between weeks 0 and 8 (1.4 points [95% confidence interval 0.3, 2.6; p = 0.018]). However, there were no statistically significant differences between the groups in night-time pain, shoulder function and SPADI scores. There was a statistically and clinically significant difference (p = 0.001) within the groups for all clinical outcomes between weeks 0 and 8, and between weeks 0 and 12.
There were no significant differences in the treatments; however, both forms of treatment were associated with a significant improvement in shoulder pain, function and disability.
本研究旨在确定与后路注射相比,肩峰下注射的外侧入路治疗肩峰下撞击综合征的有效性。
在门诊社区肌肉骨骼服务中心进行了一项实用的随机对照试验。样本包括80名18岁及以上患有肩峰下撞击综合征的成年人。干预组采用外侧入路,使用21号绿色针头,注射40mg/ml曲安奈德(康宁克通)4ml和4ml 1%利多卡因进行单次肩峰下注射。对照组接受相同治疗,只是注射采用后路入路。观察指标为在随访8周和12周时,使用0-10数字疼痛量表测量的疼痛以及肩痛和功能障碍指数(SPADI)评分。
在0至8周期间,日间疼痛改善方面(评分的平均变化)出现了中等程度但在统计学和临床上有显著意义的差异,外侧组(平均 = 4.0)优于后路组(平均 = 2.0)(1.4分[95%置信区间0.3, 2.6;p = 0.018])。然而,两组在夜间疼痛、肩部功能和SPADI评分方面没有统计学上的显著差异。在0至8周以及0至12周期间,所有临床结局在组内均存在统计学和临床上的显著差异(p = 0.001)。
两种治疗方法没有显著差异;然而,两种治疗方式均与肩部疼痛、功能和功能障碍的显著改善相关。